within Pharmacolibrary.Drugs.ATC.A;

model A10BD21
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.75,
    Cl             = 0.00021,
    adminDuration  = 600,
    adminMass      = 5 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.057,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008833333333333333,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BD21</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Saxagliptin and dapagliflozin is a fixed-dose combination drug used to treat type 2 diabetes mellitus in adults. Saxagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor and dapagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. This combination helps to improve glycemic control by targeting different mechanisms. The drug is approved for clinical use.</p><h4>Pharmacokinetics</h4><p>No population pharmacokinetic models or detailed PK parameters published in the literature for the fixed-dose combination. Individual PK parameters for saxagliptin and dapagliflozin are available but no combined PK study found. Estimates below are based on typical adult values for each component after oral administration.</p><h4>References</h4><ol><li><p>Boulton, DW, et al., &amp; Lacreta, F (2013). Simultaneous oral therapeutic and intravenous ¹⁴C-microdoses to determine the absolute oral bioavailability of saxagliptin and dapagliflozin. <i>British journal of clinical pharmacology</i> 75(3) 763–768. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2012.04391.x&quot;>10.1111/j.1365-2125.2012.04391.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22823746/&quot;>https://pubmed.ncbi.nlm.nih.gov/22823746</a></p></li><li><p>Vakkalagadda, B, et al., &amp; Boulton, DW (2016). Lack of a Pharmacokinetic Interaction Between Saxagliptin and Dapagliflozin in Healthy Subjects: A Randomized Crossover Study. <i>Clinical therapeutics</i> 38(8) 1890–1899. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2016.07.005&quot;>10.1016/j.clinthera.2016.07.005</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27491280/&quot;>https://pubmed.ncbi.nlm.nih.gov/27491280</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BD21;
